Christopher J. Senner Sells 29,314 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) CFO Christopher J. Senner sold 29,314 shares of the firm’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.14, for a total transaction of $1,059,407.96. Following the completion of the transaction, the chief financial officer now directly owns 779,607 shares of the company’s stock, valued at approximately $28,174,996.98. This trade represents a 3.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Exelixis Trading Up 0.3 %

Shares of Exelixis stock opened at $37.65 on Friday. Exelixis, Inc. has a 12 month low of $20.14 and a 12 month high of $38.43. The stock’s fifty day moving average price is $34.42 and its 200-day moving average price is $31.54. The firm has a market cap of $10.54 billion, a P/E ratio of 21.27, a P/E/G ratio of 1.13 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Seizert Capital Partners LLC boosted its stake in Exelixis by 8.0% in the 3rd quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company’s stock worth $12,195,000 after purchasing an additional 34,875 shares in the last quarter. Los Angeles Capital Management LLC grew its holdings in Exelixis by 124.0% during the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after acquiring an additional 991,494 shares during the period. Tri Ri Asset Management Corp acquired a new stake in Exelixis during the third quarter worth about $4,396,000. China Universal Asset Management Co. Ltd. raised its position in Exelixis by 60.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 54,863 shares of the biotechnology company’s stock valued at $1,424,000 after acquiring an additional 20,641 shares in the last quarter. Finally, CWA Asset Management Group LLC acquired a new position in Exelixis in the third quarter valued at approximately $577,000. Institutional investors own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Wells Fargo & Company cut shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 price objective for the company. in a research note on Monday. Oppenheimer cut Exelixis from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $41.00 to $33.00 in a research note on Friday, January 24th. Barclays raised their price objective on Exelixis from $25.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, February 13th. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Exelixis in a report on Thursday, February 13th. Finally, Bank of America downgraded Exelixis from a “buy” rating to a “neutral” rating and raised their price target for the stock from $35.00 to $39.00 in a research report on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.24.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.